Navigation Links
Calcium may be the key to understanding Alzheimer's disease
Date:7/18/2008

PHILADELPHIA, PA - Researchers at the University of Pennsylvania School of Medicine have shown that mutations in two proteins associated with familial Alzheimer's disease disrupt the flow of calcium ions within neurons. The two proteins, called PS1 and PS2 (presenilin 1 and 2), interact with a calcium release channel in an intracellular cell compartment.

"The 'calcium dysregulation' hypothesis for inherited, early onset familial Alzheimer's disease has been suggested by previous research findings, but our current study identifies a molecular mechanism that makes this hypothesis very compelling," says lead author J. Kevin Foskett, PhD, Professor of Physiology. "Mutated PS1 and PS2 caused exaggerated cellular calcium signaling in cells through a calcium channel in the endoplasmic reticulum called the inositol trisphosphate receptor [InsP3R], suggesting that it or other proteins in this calcium signaling pathway could be targets for new Alzheimer's disease therapies." The study appeared in the June 26 issue of Neuron.

Alzheimer's disease affects as many as 5 million Americans, 5 percent of whom have the familial form. The hallmark of the disease is the accumulation of tangles and plaques of amyloid beta protein in the brain. "The amyloid hypothesis has long been invoked to explain the cause of Alzheimer's" says Foskett. In the Neuron study, cells that carried the disease-causing mutated form of PS1 showed increased processing of amyloid beta that depended on the interaction of the PS proteins with the InsP3R. This observation links mis-regulation of calcium inside cells with the production of amyloid, a characteristic feature in the brains of people with Alzheimer's disease.

Current therapies for Alzheimer's include drugs that treat the symptoms of cognitive loss and dementia. Drugs that address the pathology of Alzheimer's are only experimental. For example, a vaccine that stimulates antibodies to amyloid beta is currently being investigated. But these new observations suggest that new approaches could be explored. The next steps are to find out if other mutations in PS1 and PS2 that cause Alzheimer's disease have a similar effect on calcium signaling in the brain, and to identify drugs that might inhibit the interaction between InsP3R and PS1 or PS2 specifically in the brain.

"The significance of identifying the molecular mechanism and pathway of disrupted calcium signaling is that a number of novel treatment targets can now be developed and tested," says Foskett.

The central role of calcium signaling disruptions in Alzheimer's is strengthened by another study in which the Foskett laboratory was involved. This research was published in the June 27 issue of Cell. Investigators discovered a new gene that influences calcium regulation and amyloid beta levels in the brain. In this genetic study, a polymorphism in the gene CALHM1 significantly increased the risk of sporadic, late-onset Alzheimer's, the more common form of disease. The Foskett lab was responsible for showing that the Alzheimer's disease-associated polymorphism disrupts the gene's function in cellular calcium regulation. These investigations were led by a group from The Feinstein Institute for Medical Research, North Shore in Manhasset, NY and the Albert Einstein College of Medicine, Bronx, NY.

"Calcium is the common denominator in our two studies, strongly suggesting that it plays an important role in the development of Alzheimer's disease," notes Foskett. "However, our experiments have identified calcium inside cells as the important feature. No one should consider modifying their dietary intake of calcium as a strategy to limit the risk of developing Alzheimer's disease, because the body very effectively regulates the amount of calcium absorbed from food and the levels in the blood and brain. And it is also very important for people who take calcium channel blockers, for cardiovascular problems for example, not to alter their medication regime as a response to our studies"


'/>"/>

Contact: Karen Kreeger
karen.kreeger@uphs.upenn.edu
215-349-5658
University of Pennsylvania School of Medicine
Source:Eurekalert

Related medicine news :

1. New study finds coronary arterial calcium scans help detect overall death risk in the elderly
2. Arterial Calcium Scans Can Predict Death Risk
3. New Calcium Measure Better Predictor of Heart Risks
4. Coronary calcium distribution tied to heart attack risk
5. Study shows that administering calcium and magnesium effectively reduces neurological sensitivity
6. African Americans at Risk for Low Calcium Intake - New Survey Finds Those Experiencing Symptoms of Lactose Intolerance May be Sidelining Dairy in Their Diets
7. Calcium Scans Help Predict Coronary Risk
8. High Calcium Intake May Not Help Prevent Fractures, Reports The Harvard Health Letter
9. Scripps scientists find calcium channel blockers help normalize lysosomal storage disease cells
10. Calcium Supplements Could Raise Heart Risks in Postmenopausal Women
11. Coronary Artery Calcium May Raise Womens Heart Risk
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... ... ... Lori G. Cohen and Sara K. Thompson , shareholders in global law ... 21st Drug & Medical Device Litigation Conference , taking place in New York Dec. ... chairs the firm’s Pharmaceutical, Medical Device & Health Care Litigation Practice and the Trial ...
(Date:12/2/2016)... , ... December 02, 2016 , ... Advanced Inc., a ... has appointed Jason Bice, CPA, MBA to serve as Advanced Inc.’s Chief Financial Officer, ... Inc. , Jason brings extensive financial and operational leadership experience to Advanced Inc. ...
(Date:12/2/2016)... ... ... With the number of pain management programs available for people suffering with ... that works for them. When an inventor from Suisun City, Calif., was unsuccessful in ... share it with others. , He developed a prototype for PRO GO MASSAGE to ...
(Date:12/2/2016)... ... December 02, 2016 , ... CloudLIMS.com, a ... SaaS LIMS, CloudLIMS Lite. CloudLIMS Lite helps biobanks, clinical, research and testing laboratories ... and disposal. The new version is a faster and a more efficient product, ...
(Date:12/2/2016)... ... 02, 2016 , ... Yisrayl Hawkins, at The House of Yahweh in Abilene, ... into Bible Prophecy. Yisrayl says this generation, known as the Last Generation, started in ... the details line up exactly with Bible Prophecy – a protected way for those ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... , Dec. 2, 2016  Maxor National Pharmacy Services, ... of Pharmaceutical Specialties, Inc. ("PSI").  The combination of ... Georgia -based PSI bring together both company,s clinical ... manufacturers, and payers an industry-leading specialty pharmacy. About ... , , ...
(Date:12/2/2016)... 2, 2016 Lianluo Smart Limited (Nasdaq: ... Company") which develops, markets and sells medical devices ... China and international markets, recently attended ... Treatment New Progress Forum, co-hosted by the Institute ... , Guangdong Provincial People,s Hospital and Cardiology ...
(Date:12/2/2016)... Dec. 1, 2016 The concept of rare diseases ... given to this sector has been taking shape in ... the political aspects and initiatives related to orphan medicinal products ... the level of member states individually. Many member states in ... the space of orphan medicinal products, the result of which ...
Breaking Medicine Technology: